azd8630
Small moleculeexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 3, 2021 (NCT05110976)
Timeline
Indications
Studied for
Mechanism of action
- Thymic stromal lymphopoietinINHIBITOR
TSLP inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07065331 | Phase 1 | Jun 11, 2025 | AstraZeneca |
| NCT06795906 | Phase 1/Phase 2 (Phase 2) | Jan 28, 2025 | AstraZeneca, Parexel |
| NCT06529419 | Phase 2 | Aug 30, 2024 | AstraZeneca |
| NCT06531811 | Phase 1 | Aug 6, 2024 | AstraZeneca |
| NCT05110976 | Phase 1 | Dec 3, 2021 | AstraZeneca |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 5 | 5 | 2 | 2021 |
| Parexel | For profit | 1 | 0 | 1 | 2025 |
2 organizations
Page 1 / 1